Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bicifadine SR in diabetic peripheral neuropathy
NCT00597649Phase 2Terminated
- Sponsor
- XTL Biopharmaceuticals Ltd.
- Start
- Oct 2007
- Primary completion
- Dec 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of bicifadine in diabetic peripheral neuropathy (DPN) (2 arms), sponsored by XTL Biopharmaceuticals Ltd. Primary endpoints: Pain at 52 weeks and Safety at 52 weeks. Started Oct 2007; status: terminated.
02
Drugs
bicifadine
03
Conditions
diabetic peripheral neuropathy (DPN)
Beyond the preview
Go deeper on NCT00597649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00597649.